Cardiac allograft vasculopathy

Reviews in Cardiovascular Medicine

Volumn 12, Issue 3, 2011, Pages 143-152

  Lee, Michael S ^a   Finch, Will ^a   Weisz, Giora ^b   Kirtane, Ajay J ^b  

^a UCLA MEDICAL CENTER   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

Drug eluting stent; Heart transplantation

Indexed keywords

AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PACLITAXEL; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ANGIOCARDIOGRAPHY; APOPTOSIS; ARTERY BYPASS; BARE METAL STENT; BODY MASS; CARDIAC ALLOGRAFT VASCULOPATHY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST INDUCED NEPHROPATHY; CORONARY ARTERY RECANALIZATION; CORONARY FLOW RESERVE; DISEASE COURSE; DRUG ELUTING STENT; FRACTIONAL FLOW RESERVE; GLUCOSE INTOLERANCE; HEART INFARCTION; HEART TRANSPLANTATION; HOMOZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; LYMPHOCYTIC INFILTRATION; MOUTH ULCER; MYOCARDIAL PERFUSION IMAGING; NEPHROTOXICITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REVIEW; RISK FACTOR; SMOKING; SMOOTH MUSCLE FIBER; STRESS ECHOCARDIOGRAPHY; ALLOTRANSPLANTATION; CORONARY ARTERY DISEASE; REOPERATION; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; REOPERATION; RISK ASSESSMENT; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84855387684     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm0578     Document Type: Review

References (111)

1. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;122:173-183.
2. Ross M, Kouretas P, Gamberg P, et al. Ten- and 20-year survivors of pediatric orthotopic heart transplantation. J Heart Lung Transplant. 2006;25:261-270. (Pubitemid 43290654)
3. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult heart transplant report. J Heart Lung Transplant. 2005;24:945-955. (Pubitemid 41127174)
4. Costanzo MR, Naftel DC, Pritzker MR, et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant. 1998;17:744-753. (Pubitemid 28396983)
5. Roussel JC, Baron O, Périgaud C, et al. Outcome of heart transplants 15 to 20 years ago: graft survival, post-transplant morbidity, and riskfactors for mortality. J Heart Lung Transplant. 2008;27:486-493. (Pubitemid 351602170)
6. Syeda B, Roedler S, Schukro C, et al. Transplant coronary artery disease: incidence, progression and interventional revascularization. Int J Cardiol. 2005;104:269-274. (Pubitemid 41375585)
7. Haddad M, Pflugfelder PW, Guiraudon C, et al. Angiographic, pathologic, and clinical relationships in coronary artery disease in cardiac allografts. J Heart Lung Transplant. 2005;24:1218-1225. (Pubitemid 41247801)
8. van Loosdregt J, van Oosterhout MF, Bruggink AH, et al. The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response. Circulation. 2006;114:1599-1607. (Pubitemid 44547430)
9. Tanaka M, Zwierzchoniewska M, Mokhtari GK, et al. Progression of alloresponse and tissue-specific immunity during graft coronary artery disease. Am J Transplant. 2005;5:1286-1296. (Pubitemid 40839416)
10. Vasilescu ER, Ho EK, de la Torre L, et al. Anti-HLA antibodies in heart transplantation. Transpl Immunol. 2004;12:177-183. (Pubitemid 38223978)
11. Raichlin E, Bae JH, Kushwaha SS, et al. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol. 2009;53:1279-1286.
12. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res. 2006;99:801-815. (Pubitemid 44556379)
13. Weis M, Cooke JP. Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway. Arterioscler Thromb Vasc Biol. 2003;23:567-575. (Pubitemid 36438067)
14. El-Hamamsy I, Stevens LM, Vanhoutte PM, Perrault LP. Injury of the coronary endothelium at implantation increases endothelial dysfunction and intimal hyperplasia after heart transplantation. J Heart Lung Transplant. 2005;24:251-258. (Pubitemid 40312048)
15. Murata S, Miniati DN, Kon MH, et al. Superoxide dismutase mimetic m40401 reduces ischemia-reperfusion injury and graft coronary artery disease in rodent cardiac allografts. Transplantation. 2004;78:1166-1171. (Pubitemid 39426435)
16. Tanaka M, Mokhtari GK, Terry RD. el al. Overexpression of human copper/zinc superoxide dismutase (SOD1) suppresses ischemia-reperfusion injury and subsequent development of graft coronary artery disease in murine cardiac grafts. Circulation. 2004;110:II200-II206. (Pubitemid 39263723)
17. Uehara S, Chase CM, Kitchens WH, et al. NK cells can trigger allograft vasculopathy: the role of hybrid resistance in solid organ allografts. J Immunol. 2005;175:3424-3430. (Pubitemid 41170566)
18. Chu KE, Ho EK, de la Torre L, et al. The relationship of nodular endocardial infiltrates (Quilty lesions) to survival, patient age, anti-HLA antibodies, and coronary artery disease following heart transplantation. Cardiovasc Pathol. 2005;14:219-224. (Pubitemid 40977867)
19. Ternstrom L, Jeppsson A, Ricksten A, Nilsson F. Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy. J Heart Lung Transplant. 2005;24:433-438. (Pubitemid 40403800)
20. Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111(2 Suppl):S460-S475. (Pubitemid 36223285)
21. De Souza AI, Wait R, Mitchell AG, et al. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ Res. 2005;97:192-198. (Pubitemid 41033476)
22. Densem CG, Hutchinson IV, Yonan N, Brooks NH. Donor and recipient-transforming growth factor-beta 1 polymorphism and cardiac transplant-related coronary artery disease. Transpl Immunol. 2004;13:211-217. (Pubitemid 39307046)
23. Li H, Tanaka K, Oeser B, et al. Vascular remodelling after cardiac transplantation: a 3-year serial intravascular ultrasound study. Eur Heart J. 2006;27:1671-1677. (Pubitemid 44025353)
24. Atkinson C, Southwood M, Pitman R, et al. Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy. J Heart Lung Transplant. 2005;24:551-558. (Pubitemid 40693877)
25. Holweg CT, Balk AH, Snaathorst J, et al. Intragraft heme oxygenase-1 and coronary artery disease after heart transplantation. Transpl Immunol. 2004;13:265-272. (Pubitemid 39602593)
26. Li H, Tanaka K, Anzai H, et al. Influence of preexisting donor atherosclerosis on the development of cardiac allograft vasculopathy and outcomes in heart transplant recipients. J Am Coll Cardiol. 2006;47:2470-2476. (Pubitemid 43866359)
27. Bader FM, Kfoury AG, Gilbert EM, et al. Percutaneous coronary interventions with stents in cardiac transplant recipients. J Heart Lung Transplant. 2006;25:298-301. (Pubitemid 43290660)
28. Bae JH, Rihal CS, Edwards BS, et al. Association of angiotensin- converting enzyme inhibitors and serum lipids with plaque regression in cardiac allograft vasculopathy. Transplantation. 2006;82:1108-1111. (Pubitemid 44632129)
29. Kocík M, Málek I, Janek B, et al. Risk factors for the development of coronary artery disease of a grafted heart as detected very early after orthotopic heart transplantation. Transpl Int. 2007;20:666-674. (Pubitemid 47024914)
30. Topkara VK, Dang NC, John R, et al. A decade experience of cardiac retransplantation in adult recipients. J Heart Lung Transplant. 2005;24:1745-1750. (Pubitemid 41641845)
31. Botha P, Peaston R, White K, et al. Smoking after cardiac transplantation. Am J Transplant. 2008;8:866-871. (Pubitemid 351347743)
32. Kato T, Chan MC, Gao SZ, et al. Glucose intolerance, as reflected by hemoglobin A1c level, is associated with the incidence and severity of transplant coronary artery disease. J Am Coll Cardiol. 2004;43:1034-1041. (Pubitemid 38352985)
33. Bozbas H, Altin C, Yildirir A, et al. Lipid profiles of patients with a transplanted heart before and after the operation. Transplant Proc. 2008;40:263-266. (Pubitemid 351186641)
34. Grattan MT, Moreno-Cabral CE, Starnes VA, et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-3566. (Pubitemid 19155945)
35. Hussain T, Burch M, Fenton MJ, et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation. 2007;115:1798-1805. (Pubitemid 46648617)
36. Shiba N, Chan MC, Kwok BW, et al. Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. J Heart Lung Transplant. 2004;23:155-164. (Pubitemid 38175292)
37. Walker AH, Fildes JE, Leonard CT, Yonan N. The influence of donor age on transplant coronary artery disease and survival post heart transplantation: is it safe to extend donor age? Transplant Proc. 2004;36:3139-3141. (Pubitemid 41126759)
38. Radovancevic B, Poindexter S, Birovljev S, et al. Risk factors for development of accelerated coronary artery disease in cardiac transplant recipients. Eur J Cardiothorac Surg. 1990;4:309-312.
39. Dobbels F, De Geest S, van Cleemput J, et al. Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant. 2004;23:1245-1251. (Pubitemid 39472902)
40. Raichlin E, Edwards BS, Kremers WK, et al. Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. J Heart Lung Transplant. 2009;28:320-327.
41. Price JF, Towbin JA, Dreyer WJ, et al. Symptom complex is associated with transplant coronary artery disease and sudden death/resuscitated sudden death in pediatric heart transplant recipients. J Heart Lung Transplant. 2005;24:1798- 1803.
42. Aranda JM Jr, Hill J. Cardiac transplant vasculopathy. Chest. 2000;118:1792-1800. (Pubitemid 32001812)
43. Uretsky BF, Murali S, Reddy PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation. 1987;76:827-834. (Pubitemid 17151341)
44. Gao SZ, Schroeder JS, Hunt SA, et al. Acute myocardial infarction in cardiac transplant recipients. Am J Cardiol. 1989;64:1093-1097. (Pubitemid 19279983)
45. Smart FW, Ballantyne CM, Cocanougher B, et al. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplant. Am J Cardiol. 1991;67:243-247.
46. Spes CH, Klauss V, Mudra H, et al. Diagnostic and prognostic value of serial dobutamine stress echocardiography for noninvasive assessment of cardiac allograft vasculopathy. Circulation. 1999;100:509-515.
47. Elhendy A, Sozzi FB, van Domburg RT, et al. Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis. J Heart Lung Transplant. 2000;19:360-366. (Pubitemid 30211659)
48. Rodrigues AC, Bacal F, Medeiros CC, et al. Noninvasive detection of coronary allograft vasculopathy by myocardial contrast echocardiography. J Am Soc Echocardiogr. 2005;18:116-121. (Pubitemid 40170038)
49. Bogot NR, Durst R, Shaham D, Admon D. Cardiac CT of the transplanted heart: indications, technique, appearance, and complications. Radiographics. 2007;27:1297-1309.
50. Gregory SA, Ferencik M, Achenbach S, et al. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol. 2006;98:877-884. (Pubitemid 44402254)
51. Sigurdsson G, Carrascosa P, Yamani MH, et al. Detection of transplant coronary artery disease using multidetector computed tomography with adaptative multisegment reconstruction. J Am Coll Cardiol. 2006;48:772-778. (Pubitemid 44202580)
52. Iyengar S, Feldman DS, Cooke GE, et al. Detection of coronary artery disease in orthotopic heart transplant recipients with 64-detector row computed tomography angiography. J Heart Lung Transplant. 2006;25:1363-1366. (Pubitemid 44692497)
53. Kass M, Allan R, Haddad H. Diagnosis of graft coronary artery disease. Curr Opin Cardiol. 2007;22:139-145. (Pubitemid 46220270)
54. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29:717-727.
55. Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2001;37:1478-1492.
56. Tuzcu EM, Kapadia SR, Sachar R, et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45:1538-1542. (Pubitemid 40615631)
57. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45:1532-1537. (Pubitemid 40615630)
58. König A, Kilian E, Sohn HY, et al. Assessment and characterization of time-related differences in plaque composition by intravascular ultrasound-derived radiofrequency analysis in heart transplant recipients. J Heart Lung Transplant. 2008;27:302-309. (Pubitemid 351375110)
59. Kapadia SR, Ziada KM, L'Allier PL, et al. Intravascular ultrasound imaging after cardiac transplantation: advantage of multi-vessel imaging. J Heart Lung Transplant. 2000;19:167-172. (Pubitemid 30088988)
60. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant. 2006;6:1248-1256. (Pubitemid 44030306)
61. Clausell N, Butany J, Molossi S, et al. Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. J Am Coll Cardiol. 1995;26:110-119.
62. Fearon WF, Nakamura M, Lee DP, et al. Simultaneous assessment of fractional and coronary flow reserves in cardiac transplant recipients: Physiologic Investigation for Transplant Arteriopathy (PITA Study). Circulation. 2003;108:1605-1610. (Pubitemid 37187788)
63. Shirakawa I, Sata M, Saiura A, et al. Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Biomed Pharmacother. 2007;61:154-159. (Pubitemid 46562557)
64. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995;333:621-627.
65. Kobashigawa JA. Statins and cardiac allograft vasculopathy after heart transplantation. Semin Vasc Med. 2004;4:401-406. (Pubitemid 40577829)
66. Crawford SE, Mavroudis C, Backer CL, et al. Captopril suppresses post-transplantation angiogenic activity in rat allograft coronary vessels. J Heart Lung Transplant. 2004;23:666-673. (Pubitemid 38721434)
67. Erinc K, Yamani MH, Starling RC, et al. The effect of combined angiotensin-converting enzyme inhibition and calcium antagonism on allograft coronary vasculopathy validated by intravascular ultrasound. J Heart Lung Transplant. 2005;24:1033-1038. (Pubitemid 41127185)
68. Yamamoto T, Sata M, Fukuda D, Takamoto S. The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy. Basic Res Cardiol. 2005;100:84-91. (Pubitemid 40069109)
69. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 2001;7:738-741. (Pubitemid 32588032)
70. Yousufuddin M, Cook DJ, Starling RC, et al. Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease. J Am Coll Cardiol. 2004;43:1565-1573. (Pubitemid 38561335)
71. Lijkwan MA, Cooke DT, Martens JM, et al. Cyclosporine treatment of high dose and long duration reduces the severity of graft coronary artery disease in rodent cardiac allografts. J Heart Lung Transplant. 2005;24:439-445. (Pubitemid 40403801)
72. Soukiasian HJ, Czer LS, Wang HM, et al. Inhibition of graft coronary arteriosclerosis after heart transplantation. Am Surg. 2004;70:833-840.
73. Lungu AO, Jin ZG, Yamawaki H, et al. Cyclosporin A inhibits flow-mediated activation of endothelial nitric-oxide synthase by altering cholesterol content in caveolae. J Biol Chem. 2004;279:48794-48800. (Pubitemid 39625758)
74. Oriji GK, Keiser HR. Nitric oxide in cyclosporine A-induced hypertension: role of protein kinase C. Am J Hypertens. 1999;12:1091-1097.
75. Coffman TM, Carr DR, Yarger WE, Klotman PE. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation. 1987;43:282-285. (Pubitemid 17038983)
76. Rosenthal RA, Chukwuogo NA, Ocasio VH, Kahng KU. Cyclosporine inhibits endothelial cell prostacyclin production. J Surg Res. 1989;46:593-596. (Pubitemid 19170327)
77. Haug C, Duell T, Voisard R, et al. Cyclosporine A stimulates endothelin release. J Cardiovasc Pharmacol. 1995;26:S239-S241.
78. Takeda Y, Miyamori I, Wu P, et al. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension. 1995;26:932-936.
79. Humiston D, Taylor D, Kfoury A, et al. Mycophenolate mofetil history and introduction into clinical heart transplantation. Cardiovasc Eng. 1997;2:198-203.
80. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66:507-515. (Pubitemid 28415379)
81. Kobashigawa JA, Tobis JM, Mentzer RM, et al. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am J Transplant. 2006;6:993-997. (Pubitemid 44356649)
82. Keogh A. Long-term benefits of mycophenolate mofetil after heart transplantation. Transplantation. 2005;79:S45-S46. (Pubitemid 40293576)
83. Ikonen TS, Gummert JF, Serkova N, et al. Efficacies of sirolimus (rapamycin) and cyclosporine in allograft vascular disease in non-human primates trough levels of sirolimus correlate with inhibition of progression of arterial intimal thickening. Transpl Int. 2000;13:S314-S320.
84. Murphy GJ, Bicknell GR, Nicholson ML. Rapamycin inhibits vascular remodeling in an experimental model of allograft vasculopathy and attenuates associated changes in fibrosis-associated gene expression. J Heart Lung Transplant. 2003;22:533-541. (Pubitemid 36549052)
85. Mehra MR, Uber PA. TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant. 2003;22:501-504. (Pubitemid 36549047)
86. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation. 2004;110:2694-2700. (Pubitemid 39453021)
87. Hafizi S, Mordi VN, Andersson KM, et al. Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling. Vascul Pharmacol. 2004;41:167-176. (Pubitemid 39646491)
88. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant. 2005;24:184-189. (Pubitemid 40215595)
89. Raichlin E, Bae JH, Khalpey Z, et al. Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. Circulation. 2007;116:2726-2733. (Pubitemid 350291245)
90. Raichlin E, Prasad A, Kremers WK, et al. Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients. Eur Heart J. 2009;30:1356-1363.
91. Ramzy D, Rao V, Tumiati L, et al. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine. Circulation. 2006;114:I-214-I-219.
92. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am J Transplant. 2006;6:986-992. (Pubitemid 44356648)
93. Tanaka K, Li H, Curran PJ, et al. Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol. 2006;97:1192-1197.
94. Simpson L, Lee EK, Hott BJ, et al. Long-term results of angioplasty vs stenting in cardiac transplant recipients with allograft vasculopathy. J Heart Lung Transplant. 2005;24:1211-1217. (Pubitemid 41247800)
95. Benza RL, Zoghbi GJ, Tallaj J, et al. Palliation of allograft vasculopathy with transluminal angioplasty: a decade of experience. J Am Coll Cardiol. 2004;43:1973-1981. (Pubitemid 38691130)
96. Wellnhofer E, Hiemann NE, Hug J, et al. A decade of percutaneous coronary interventions in cardiac transplant recipients: a monocentric study in 160 patients. J Heart Lung Transplant. 2008;27:17-25.
97. Jonas M, Fang JC, Wang JC, et al. In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol. 2006;48:453-461. (Pubitemid 44093942)
98. Hognestad A, Endresen K, Wergeland R, et al. Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant. 2005;24:1026-1032. (Pubitemid 41127184)
99. McKay M, Pinney S, Gorwara S, et al. Antihuman leukocyte antigen antibodies are associated with restenosis after percutaneous coronary intervention for cardiac allograft vasculopathy. Transplantation. 2005;79:1581-1587. (Pubitemid 40847591)
100. Lee MS, Kobashigawa JA, Tobis JM. Comparison of percutaneous coronary intervention with bare-metal and drug-eluting stents for cardiac allograft vasculopathy. JACC Cardiovasc Interv. 2008;1:710-715.
101. Zakliczynski M, Lekston A, Osuch M, et al. Comparison of long-term results of drugeluting stent and bare metal stent implantation in heart transplant recipients with coronary artery disease. Transplant Proc. 2007;39:2859-2861. (Pubitemid 350088098)
102. Lee MS, Tarantini G, Xhaxho J, et al. Sirolimus-versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy. JACC Cardiovasc Interv. 2010;3:378-382.
103. Lee MS, Yang T, Fearon WF, et al. Long-term outcomes after percutaneous coronary intervention of left main coronary artery for treatment of cardiac allograft vasculopathy after orthotopic heart transplantation. Am J Cardiol. 2010;106:1086-1089.
104. Musci M, Loebe M, Wellnhofer E, et al. Coronary angioplasty, bypass surgery, and retransplantation in cardiac transplant patients with graft coronary disease. Thorac Cardiovasc Surg. 1998;46:268-274. (Pubitemid 28562036)
105. Goerler H, Simon A, Warnecke G, et al. Cardiac surgery late after heart transplantation: a safe and effective treatment option. J Thorac Cardiovasc Surg. 2010;140:433-439.
106. Rothenburger M, Hülsken G, Stypmann J, et al. Cardiothoracic surgery after heart and heartlung transplantation. Thorac Cardiovasc Surg. 2005;53:85-92. (Pubitemid 40545327)
107. Musci M, Pasic M, Meyer R, et al. Coronary artery bypass grafting after orthotopic heart transplantation. Eur J Cardiothorac Surg. 1999;16:163-168. (Pubitemid 29376670)
108. Patel VS, Radovancevic B, Springer W, et al. Revascularization procedures in patients with transplant coronary artery disease. Eur J Cardiothorac Surg. 1997;11:895-901. (Pubitemid 27261890)
109. Bhama JK, Nguyen DQ, Scolieri S, et al. Surgical revascularization for cardiac allograft vasculopathy: is it still an option? J Thorac Cardiovasc Surg. 2009;137:1488-1492.
110. Mahle WT, Vincent RN, Kanter KR. Cardiac retransplantation in childhood: analysis of data from the United Network for Organ Sharing. J Thorac Cardiovasc Surg. 2005;130:542-546. (Pubitemid 41074190)
111. John R, Chen JM, Weinberg A, et al. Long-term survival after cardiac retransplantation: a twenty-year single-center experience. J Thorac Cardiovasc Surg. 1999;117:543-555. (Pubitemid 29117535)